EMA – Northern Ireland: Q&A to Stakeholders on the implications of Regulation (EU) 2023/1182 for centrally authorised medicinal products for human use
The EMA issued a Practical guidance on the applicable rules to centrally authorised medicinal products for human use intended to be placed on the market in Northern Ireland before and after the application of Regulation (EU) 2023/1182 in the form of a Q&A.
More information on the EMA Website.
OpenEdition vous propose de citer ce billet de la manière suivante :
vroby (31 mai 2024). EMA – Northern Ireland: Q&A to Stakeholders on the implications of Regulation (EU) 2023/1182 for centrally authorised medicinal products for human use. ELSIBI. Consulté le 19 février 2026 à l’adresse https://doi.org/10.58079/11rmy





